1. Home
  2. Programs
  3. CME/CE
advertisement

Cases From the Real World: 72-Year-Old Woman With CRVO

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters

  • Overview

    Patients with retinal vein occlusion-macular edema (RVO-ME) with good disease control often desire to prolong treatment intervals as much as possible. How much durability can we expect from second-generation retinal agents, like faricimab and aflibercept 8 mg, in these patients?  

  • Target Audience

    This certified continuing education (CME) activity is designed for ophthalmologists involved in the management of patients with retinal diseases.

  • Grantor Statement

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to: 

    • Infer the potential efficacy and durability of second-generation agents, based on clinical trials and real-world studies
    • Discuss the clinical indicators and other nonclinical considerations involved in tailoring treatment with second-generation agents

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education  
     

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 
    Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Faculty


    Ferhina     S Ali, MD, MPH, FASRS 
    Assistant Professor of Ophthalmology
    New York Medical College
    Westchester Medical Center 
    Valhalla, NY

     

    Yasha S. Modi, MD, MHS  
    Associate Professor of Ophthalmology 
    Department of Ophthalmology 
    Director of Tele-Retina  
    NYU Langone Health 
    New York, NY 

  • Disclosure of Relevant Financial Relationships

    DISCLOSURE POLICY
    In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity. 

    The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months. 

    Ferhina S. Ali, MD, MPH, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum, Apellis Pharmaceuticals, Astellas Pharma Global Development, EyePoint Pharmaceuticals, Genentech, Ocuphire, Ocuterra, Optomed, Outlook Therapeutics. Grant/Research Support:Apellis Pharmaceuticals, Astellas Pharma Global Development.

    Yasha S. Modi, MD, MHS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Apellis Pharmaceuticals, Astellas, EyePoint Pharmaceuticals, Genentech, Notal Vision, Opthea, Regeneron, Topcon. Grant/Research Support: Genentech. 

    The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies. 

  • Disclaimer

    OFF-LABEL STATEMENT 
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    DISCLAIMER 
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech. 

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters

  • Overview

    Patients with retinal vein occlusion-macular edema (RVO-ME) with good disease control often desire to prolong treatment intervals as much as possible. How much durability can we expect from second-generation retinal agents, like faricimab and aflibercept 8 mg, in these patients?  

  • Target Audience

    This certified continuing education (CME) activity is designed for ophthalmologists involved in the management of patients with retinal diseases.

  • Grantor Statement

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to: 

    • Infer the potential efficacy and durability of second-generation agents, based on clinical trials and real-world studies
    • Discuss the clinical indicators and other nonclinical considerations involved in tailoring treatment with second-generation agents

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education  
     

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 
    Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Faculty


    Ferhina     S Ali, MD, MPH, FASRS 
    Assistant Professor of Ophthalmology
    New York Medical College
    Westchester Medical Center 
    Valhalla, NY

     

    Yasha S. Modi, MD, MHS  
    Associate Professor of Ophthalmology 
    Department of Ophthalmology 
    Director of Tele-Retina  
    NYU Langone Health 
    New York, NY 

  • Disclosure of Relevant Financial Relationships

    DISCLOSURE POLICY
    In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity. 

    The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months. 

    Ferhina S. Ali, MD, MPH, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum, Apellis Pharmaceuticals, Astellas Pharma Global Development, EyePoint Pharmaceuticals, Genentech, Ocuphire, Ocuterra, Optomed, Outlook Therapeutics. Grant/Research Support:Apellis Pharmaceuticals, Astellas Pharma Global Development.

    Yasha S. Modi, MD, MHS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Apellis Pharmaceuticals, Astellas, EyePoint Pharmaceuticals, Genentech, Notal Vision, Opthea, Regeneron, Topcon. Grant/Research Support: Genentech. 

    The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies. 

  • Disclaimer

    OFF-LABEL STATEMENT 
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    DISCLAIMER 
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech. 

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Program Chapters

Segment Chapters

Playlist:

Recommended

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
PrevNext